JP2016510767A - 抗不安化合物の結晶形態 - Google Patents

抗不安化合物の結晶形態 Download PDF

Info

Publication number
JP2016510767A
JP2016510767A JP2015561822A JP2015561822A JP2016510767A JP 2016510767 A JP2016510767 A JP 2016510767A JP 2015561822 A JP2015561822 A JP 2015561822A JP 2015561822 A JP2015561822 A JP 2015561822A JP 2016510767 A JP2016510767 A JP 2016510767A
Authority
JP
Japan
Prior art keywords
disease
disorder
depression
compound
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015561822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510767A5 (enExample
Inventor
バーナード ルーク フリン，
バーナード ルーク フリン，
ダラム ポール，
ダラム ポール，
アンドリュー ジョン ハーヴェイ，
アンドリュー ジョン ハーヴェイ，
Original Assignee
バイオノミックス リミテッド
バイオノミックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオノミックス リミテッド, バイオノミックス リミテッド filed Critical バイオノミックス リミテッド
Publication of JP2016510767A publication Critical patent/JP2016510767A/ja
Publication of JP2016510767A5 publication Critical patent/JP2016510767A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015561822A 2013-03-15 2013-05-14 抗不安化合物の結晶形態 Pending JP2016510767A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361787436P 2013-03-15 2013-03-15
US61/787,436 2013-03-15
AU2013204159 2013-04-12
AU2013204159A AU2013204159B2 (en) 2013-03-15 2013-04-12 A Crystalline Form of an Anxiolytic Compound
PCT/AU2013/000497 WO2014138772A1 (en) 2013-03-15 2013-05-14 A crystalline form of an anxiolytic compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018018526A Division JP2018109011A (ja) 2013-03-15 2018-02-05 抗不安化合物の結晶形態

Publications (2)

Publication Number Publication Date
JP2016510767A true JP2016510767A (ja) 2016-04-11
JP2016510767A5 JP2016510767A5 (enExample) 2016-07-07

Family

ID=51628585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015561822A Pending JP2016510767A (ja) 2013-03-15 2013-05-14 抗不安化合物の結晶形態
JP2018018526A Pending JP2018109011A (ja) 2013-03-15 2018-02-05 抗不安化合物の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018018526A Pending JP2018109011A (ja) 2013-03-15 2018-02-05 抗不安化合物の結晶形態

Country Status (9)

Country Link
US (2) US9758516B2 (enExample)
EP (1) EP2970290B1 (enExample)
JP (2) JP2016510767A (enExample)
CN (2) CN105377850A (enExample)
AU (2) AU2013204159B2 (enExample)
CA (1) CA2905573C (enExample)
MX (1) MX369451B (enExample)
NZ (1) NZ712341A (enExample)
WO (1) WO2014138772A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492440A (zh) * 2013-03-15 2016-04-13 生态学有限公司 抗焦虑化合物的盐、共晶体和多晶型物
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2022003347A (es) * 2019-09-23 2022-04-11 Bionomics Ltd Formulaciones terapeuticas y usos de las mismas.
AU2023201463A1 (en) * 2023-03-08 2024-09-26 Bionomics Limited Method of treating social anxiety disorder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62129280A (ja) * 1985-10-25 1987-06-11 ビーチヤム・グループ・ピーエルシー 新規化合物、その製法及びそれを含む医薬組成物
JP2007528858A (ja) * 2004-05-07 2007-10-18 テバ ファーマシューティカル インダストリーズ リミティド ナテグリニドの多形形態
JP2010506829A (ja) * 2006-10-16 2010-03-04 バイオノミクス リミテッド 新規な抗不安薬化合物
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
WO2012151640A1 (en) * 2011-05-12 2012-11-15 Bionomics Limited Methods for preparing naphthyridines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62129280A (ja) * 1985-10-25 1987-06-11 ビーチヤム・グループ・ピーエルシー 新規化合物、その製法及びそれを含む医薬組成物
JP2007528858A (ja) * 2004-05-07 2007-10-18 テバ ファーマシューティカル インダストリーズ リミティド ナテグリニドの多形形態
JP2010506829A (ja) * 2006-10-16 2010-03-04 バイオノミクス リミテッド 新規な抗不安薬化合物
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
WO2012151640A1 (en) * 2011-05-12 2012-11-15 Bionomics Limited Methods for preparing naphthyridines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 283, JPN6015041512, 2004, pages 117 - 125, ISSN: 0003650974 *
PHARMACEUTICAL RESEARCH, vol. 12(7), JPN6017002364, 1995, pages 945 - 954, ISSN: 0003650976 *
新製剤学, JPN6012022297, 25 April 1984 (1984-04-25), pages 102 - 103, ISSN: 0003650975 *
薬剤学, vol. 66(6), JPN6016017365, 2006, pages 435 - 439, ISSN: 0003650973 *

Also Published As

Publication number Publication date
JP2018109011A (ja) 2018-07-12
EP2970290A4 (en) 2016-08-31
CN107814799A (zh) 2018-03-20
HK1220187A1 (en) 2017-04-28
US9758516B2 (en) 2017-09-12
NZ712341A (en) 2019-07-26
EP2970290A1 (en) 2016-01-20
US20170305905A1 (en) 2017-10-26
WO2014138772A1 (en) 2014-09-18
AU2013204159A1 (en) 2014-10-02
EP2970290B1 (en) 2020-07-22
CN105377850A (zh) 2016-03-02
US20160039810A1 (en) 2016-02-11
MX2015013048A (es) 2016-09-07
CA2905573A1 (en) 2014-09-18
AU2013204159B2 (en) 2015-05-07
MX369451B (es) 2019-11-08
CA2905573C (en) 2021-03-02
AU2013382559A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
JP2018109011A (ja) 抗不安化合物の結晶形態
JP2022513959A (ja) 大環状化合物及び疾患の処置におけるそれらの使用
AU2017201916B2 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
CN112920200A (zh) 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
KR20200014915A (ko) 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도
TW200817402A (en) Substituted pteridines
TW200948813A (en) Plk inhibitors
TW201014854A (en) Substituted pyrimido isoquinoline derivatives
JPWO2020128925A5 (enExample)
US11352365B2 (en) Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
HK1220187B (en) A crystalline form of an anxiolytic compound
US20250333371A1 (en) Compounds
TWI899051B (zh) 二氫唏衍生物
KR20210084592A (ko) Rho 키나아제 억제제, 이를 제조하기 위한 방법 및 이의 용도
EA040559B1 (ru) Диазабициклические замещенные имидазопиримидины и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171003